Trial Profile
Evaluation of the safety and immunogenicity of GSK Bio's HPV vaccine 580299 when administered in healthy females aged 9-25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04B
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 03 Feb 2019 Results published in the Journal of Infectious Diseases.
- 16 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Oct 2011 Planned end date changed from 1 Feb 2013 to 1 May 2013 as reported by ClinicalTrials.gov.